MRK vs MS: Which Is the Better Buy?
Side-by-side comparison of Merck & Co., Inc. and Morgan Stanley — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-20.
Merck & Co., Inc. · Healthcare
$114.27
+3.3% upside to fair value
Grade C
High Quality
VS
Morgan Stanley · Financial Services
$189.30
+45.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
MS has more upside to fair value
(+45.0%).
MS trades at a lower forward P/E
(16.4x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRK |
MS |
| Current Price |
$114.27 |
$189.30 |
| Fair Value Estimate |
$118.00 |
$274.49 |
| Upside to Fair Value |
+3.3%
|
+45.0%
|
| Market Cap |
$282.2B |
$300.6B |
| Forward P/E |
22.4x
|
16.4x
|
| EV / EBITDA |
13.5x
|
24.4x
|
| Price / Sales |
4.3x
|
2.5x
|
| Price / FCF |
20.2x
|
-16.8x
|
| Revenue Growth YoY |
+5.0%
|
+18.8%
|
| Gross Margin |
81.9%
|
58.0%
|
| Operating Margin |
27.5%
|
19.5%
|
| Return on Equity |
5.6%
|
16.7%
|
| Dividend Yield |
2.91% |
0% |
| FCF Yield |
4.95%
|
—
|
| Analyst Consensus |
Overweight
|
Hold
|
Investment Thesis
Merck delivered a clean Q1 2026 operational beat on April 30, with revenue of 16.3 billion dollars growing 5 percent year over year and Keytruda sales rising 12 percent to 8.0 billion dollars. The reported loss of 1.28 dollars per share, though better than the negative 1.47 dollar consensus estimate, reflected a 3.62 dollar per share IPR and D charge tied to the Cidara Therapeutics acquisition an…
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Accumulation Zones
| Metric |
MRK |
MS |
| Zone Low |
$88.50 |
$205.87 |
| Zone High |
$100.30 |
$233.32 |
| In Buy Zone? |
No
|
Yes
|